PDF herunterladen
Semin Reprod Med 2002; 20(4): 365-374
DOI: 10.1055/s-2002-36709
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Hyperprolactinemia: Etiology, Diagnosis, and Management

Peak Mann Mah, Jonathan  Webster
  • Endocrine Centre, Northern General Hospital, Sheffield, United Kingdom
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
21. Januar 2003 (online)

    Lizenzen und Reprints

ABSTRACT

Hyperprolactinemia is the most common endocrine disorder of the hypothalamic-pituitary axis. A prolactinoma is the most common cause of chronic hyperprolactinemia once pregnancy, primary hypothyroidism, and drugs that elevate serum prolactin levels have been excluded. Patients can present with hypogonadism, infertility, galactorrhea, osteopenia, and mass effects of the tumor. When hyperprolactinemia is confirmed, a cause for the disorder needs to be sought. This involves a careful history and examination, followed by laboratory tests and diagnostic imaging of the sella turcica. The goals of treatment are to normalize prolactin levels, restore gonadal function, and reduce the effects of chronic hyperprolactinemia. Dopamine agonists are the treatment of choice for the majority of patients. Transsphenoidal surgery is usually reserved for patients who are intolerant of or resistant to dopamine agonists or when hyperprolactinemia is caused by non-prolactin-secreting tumors compressing the pituitary stalk. Cabergoline has been shown to be more effective and better tolerated than bromocriptine. However, there are more data on the safety of the latter drug during pregnancy and bromocriptine, therefore, remains the treatment of choice in hyperprolactinemic women wishing to conceive.

KEYWORD

Hyperprolactinemia - prolactinoma - dopamine agonists - bromocriptine - cabergoline - pregnancy

REFERENCES

  • 1 Delitala G. Hyperprolactinaemia: causes, biochemical diagnosis and tests of prolactin secretion. In: Grossman A, ed. Clinical Endocrinology Oxford, UK: Blackwell Science 1998: 138-147
    Suche in Google Scholar
  • 2 Molitch M E. Disorders of prolactin secretion.  Endocrinol Metab Clin North Am . 2001;  30 585-610
    CrossrefPubMedSuche in Google Scholar
  • 3 Molitch M E. Management of prolactinomas during pregnancy.  J Reprod Med . 1999;  44 (suppl 12) 1121-1126
    PubMedSuche in Google Scholar
  • 4 Biller B M, Luciano A, Crosignani P G. Guidelines for the diagnosis and treatment of hyperprolactinemia.  J Reprod Med . 1999;  44 (suppl 12) 1075-1084
    PubMedSuche in Google Scholar
  • 5 Luciano A A. Clinical presentation of hyperprolactinemia.  J Reprod Med . 1999;  44 (suppl 12) 1085-1090
    PubMedSuche in Google Scholar
  • 6 Webster J, Scanlon M F. Prolactinomas. In: Sheaves R, Jenkins PJ, Wass JA, eds. Clinical Endocrine Oncology Oxford, UK: Blackwell Science 1997: 189-194
    Suche in Google Scholar
  • 7 Bevan J S, Webster J, Burke C W, Scanlon M F. Dopamine agonists and pituitary tumor shrinkage.  Endocr Rev . 1992;  13 220-240
    CrossrefPubMedSuche in Google Scholar
  • 8 Klibanski A, Neer R M, Beitins I Z, Ridgway E C, Zervas N T, McArthur J W. Decreased bone density in hyperprolactinemic women.  N Engl J Med . 1980;  303 1511-1514
    PubMedSuche in Google Scholar
  • 9 Biller B M, Baum H B, Rosenthal D I, Saxe V C, Charpie P M, Klibanski A. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea.  J Clin Endocrinol Metab . 1992;  75 692-697
    CrossrefPubMedSuche in Google Scholar
  • 10 Klibanski A, Biller B M, Rosenthal D I, Schoenfeld D A, Saxe V. Effects of prolactin and estrogen deficiency in amenorrheic bone loss.  J Clin Endocrinol Metab . 1988;  67 124-130
    PubMedSuche in Google Scholar
  • 11 Biller B M. Hyperprolactinemia.  Int J Fertil Womens Med . 1999;  44 74-77
    PubMedSuche in Google Scholar
  • 12 Jenkins R C, Ross R JM. Protocols for common endocrine tests. In: Grossman A, ed. Clinical Endocrinology Oxford, UK: Blackwell Science 1998: 1117-1134
    Suche in Google Scholar
  • 13 Martin T L, Kim M, Malarkey W B. The natural history of idiopathic hyperprolactinemia.  J Clin Endocrinol Metab . 1985;  60 855-858
    PubMedSuche in Google Scholar
  • 14 Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis.  J Clin Endocrinol Metab . 1989;  68 412-418
    PubMedSuche in Google Scholar
  • 15 Jeffcoate W J, Pound N, Sturrock N D, Lambourne J. Long-term follow-up of patients with hyperprolactinaemia.  Clin Endocrinol (Oxf) . 1996;  45 299-303
    CrossrefPubMedSuche in Google Scholar
  • 16 Nishioka H, Ito H, Haraoka J, Hirano A. Growth potential of female prolactinomas.  Surg Neurol . 2001;  55 213-217
    PubMedSuche in Google Scholar
  • 17 Tyrrell J B, Lamborn K R, Hannegan L T, Applebury C B, Wilson C B. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results.  Neurosurgery . 1999;  44 254-261
    CrossrefPubMedSuche in Google Scholar
  • 18 Turner H E, Adams C B, Wass J A. Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?.  Eur J Endocrinol . 1999;  140 43-47
    CrossrefPubMedSuche in Google Scholar
  • 19 Wilson C B. Surgical management of pituitary tumors.  J Clin Endocrinol Metab . 1997;  82 2381-2385
    CrossrefPubMedSuche in Google Scholar
  • 20 Bevan J S, Adams C B, Burke C W. Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy.  Clin Endocrinol (Oxf) . 1987;  26 541-556
    PubMedSuche in Google Scholar
  • 21 Landolt A M, Lomax N. Gamma knife radiosurgery for prolactinomas.  J Neurosurg . 2000;  93 (suppl 3) 14-18
    PubMedSuche in Google Scholar
  • 22 Pan L, Zhang N, Wang E M, Wang B J, Dai J Z, Cai P W. Gamma knife radiosurgery as a primary treatment for prolactinomas.  J Neurosurg . 2000;  93 (suppl 3) 10-13
    PubMedSuche in Google Scholar
  • 23 Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.  Drug Saf . 1996;  14 228-238
    PubMedSuche in Google Scholar
  • 24 Webster J, Piscitelli G, Polli A, Ferrari C I, Ismail I, Scanlon M F. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.  N Engl J Med . 1994;  331 904-909
    CrossrefPubMedSuche in Google Scholar
  • 25 Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.  Eur J Endocrinol . 1996;  135 413-420
    PubMedSuche in Google Scholar
  • 26 Webster J, Piscitelli G, Polli A. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group.  Clin Endocrinol (Oxf) . 1993;  39 323-329
    PubMedSuche in Google Scholar
  • 27 Verhelst J, Abs R, Maiter D. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.  J Clin Endocrinol Metab . 1999;  84 2518-2522
    CrossrefPubMedSuche in Google Scholar
  • 28 Di Sarno A, Landi M L, Cappabianca P. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.  J Clin Endocrinol Metab . 2001;  86 5256-5261
    CrossrefPubMedSuche in Google Scholar
  • 29 Colao A, Di Sarno A, Landi M L. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.  J Clin Endocrinol Metab . 2000;  85 2247-2252
    CrossrefPubMedSuche in Google Scholar
  • 30 Webster J. Clinical management of prolactinomas.  Baillieres Best Pract Res Clin Endocrinol Metab . 1999;  13 395-408
    CrossrefPubMedSuche in Google Scholar
  • 31 Homburg R, West C, Brownell J, Jacobs H S. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia.  Clin Endocrinol (Oxf) . 1990;  32 565-571
    PubMedSuche in Google Scholar
  • 32 Verhelst J A, Froud A L, Touzel R, Wass J A, Besser G M, Grossman A B. Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study.  Acta Endocrinol (Copenh) . 1991;  125 385-391
    PubMedSuche in Google Scholar
  • 33 van der Heijden F P, de Wit W, Brownell J, Schoemaker J, Rolland R. CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia.  Eur J Obstet Gynecol Reprod Biol . 1991;  40 111-118
    CrossrefPubMedSuche in Google Scholar
  • 34 Giusti M, Porcella E, Carraro A, Cuttica M, Valenti S, Giordano G. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients.  J Endocrinol Invest . 1994;  17 51-57
    PubMedSuche in Google Scholar
  • 35 Webster J. Cabergoline and quinagolide therapy for prolactinomas.  Clin Endocrinol (Oxf) . 2000;  53 549-550
    CrossrefPubMedSuche in Google Scholar
  • 36 Di Sarno A, Landi M L, Marzullo P. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.  Clin Endocrinol (Oxf) . 2000;  53 53-60
    CrossrefPubMedSuche in Google Scholar
  • 37 Johnston D G, Hall K, Kendall-Taylor P, Patrick D, Watson M, Cook D B. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography.  Lancet . 1984;  2 187-192
    PubMedSuche in Google Scholar
  • 38 van't Verlaat W J, Croughs R J. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas: effect on plasma prolactin and tumour size.  Clin Endocrinol (Oxf) . 1991;  34 175-178
    PubMedSuche in Google Scholar
  • 39 Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients.  J Endocrinol Invest . 1997;  20 537-546
    PubMedSuche in Google Scholar
  • 40 Karunakaran S, Page R C, Wass J A. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia.  Clin Endocrinol (Oxf) . 2001;  54 295-300
    CrossrefPubMedSuche in Google Scholar
  • 41 Rebar R W. Following patients under treatment for hyperprolactinemia.  J Reprod Med . 1999;  44 (suppl 12) 1100-1104
    PubMedSuche in Google Scholar
  • 42 Corenblum B, Donovan L. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia.  Fertil Steril . 1993;  59 671-673
    PubMedSuche in Google Scholar
  • 43 Testa G, Vegetti W, Motta T. Two-year treatment with oral contraceptives in hyperprolactinemic patients.  Contraception . 1998;  58 69-73
    CrossrefPubMedSuche in Google Scholar
  • 44 Camanni F, Ciccarelli E. Prolactinomas. In: Grossman A, ed. Clinical Endocrinology Oxford, UK: Blackwell Science 1998: 148-163
    Suche in Google Scholar
  • 45 Randeva H S, Davis M, Prelevic G M. Prolactinoma and pregnancy.  Br J Obstet Gynaecol . 2000;  107 1064-1068
    PubMedSuche in Google Scholar
  • 46 Molitch M E. Management of prolactinomas during pregnancy.  J Reprod Med . 1999;  44 (suppl 12) 1121-1126
    PubMedSuche in Google Scholar